Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase

Posted by rob on July 30, 2010 under Uncategorized | Comments are off for this article

Abstract  The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment
in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective
study of 171 CML-CP patients receiving imatinib monotherapy was done with 73 in the initial treatment group (disease course
?6 months) and 98 in the re-treatment group (disease course >6 months). Cumulative rates of complete cytogenetic response
(CCyR) at 6, 12, and 36 months after imatinib treatment in the initial and re-treatment groups were 75%, 89%, and 96%, and
48%, 77% and 84% (p?=?0.0002), respectively. The median time to CCyR in the initial and re-treatment groups was 6 months…
More